Tweet
From Dr Kwon at Mayo Clinic for Prostate Cancer Research Institute.
-
Last edited by Duck2; 01-06-2023, 06:28 AM.YOB 1957
DX 12/18, GS 8, 4+4 6/12 cores, LL Apex 100%, LM Apex 60%, LL Mid 50%, LMM 40%, LL Base 5%, LM <5%, Right side negative.
3/6/19. Post surgery Pathology Report - Grade Group 4 Intraductal Carcinoma
T3aNO, <1 mm non focal EPE, GS8, 21 mm uni-focal tumor involved 10% of prostate.
7 Nodes, SV, SM, PNI, and BNI were negative.
LVI and Cribriform pattern present.
Decipher .86 High Risk.
Post Surgery PSA
3/25/19 .03. (25 days)
4/25/19. <.03. (2 months)
5/25/19 <.02 (3 month)
5/20/22. < .02 (39 months). T=37
11/7/22. <.02 (45 months) T=54
3 Part Modality Treatment Completed
2/25/19 Robotic Laparoendoscopic Single Site Surgery outpatient Cleveland Clinic, Dr. Kaouk, surgery his #41st in US.
ART - 7/25/-9/25 2019 (78 Gy, yes, I glow in the dark).
ADT - 5/19- 5/21 Eligard and Casodex.
3 Part Modality Treatment Completed
2/25/19 Robotic Laparoendoscopic Single Site Surgery outpatient Cleveland Clinic, Dr. Kaouk, surgery #41 in US.
ART - 7/25/-9/25 2019 (78 Gy, yes, I glow in the dark).
ADT - 5/19- 5/21 Eligard and Casodex.
-
Good stuff, thanks for posting the links.
Comment